Hospital News and Research

RSS

Salamander research findings bring scientists closer to future regenerative therapies

Tissue regeneration in salamanders and newts seems like it should be the stuff of science fiction. But it happens routinely. Why can't we mammals just re-grow a limb or churn out a few new heart muscle cells as needed? New research suggests there might be a very good reason: Restricting our cells' ability to pop in and out of the cell cycle at will - a prerequisite for the cell division necessary to make new tissue - reduces the chances that they'll run amok and form potentially deadly cancers.

6 Aug 2010

Nemours applauds Senate for passing bi-partisan Healthy, Hunger-Free Kids Act of 2010

Nemours, an integrated children's health system, congratulates the United States Senate on passing the bi-partisan Healthy, Hunger-Free Kids Act of 2010, prior to the September 30th expiration of the child nutrition legislation. We applaud Senators Lincoln and Chambliss for their leadership in advancing this historic legislation.

6 Aug 2010

Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials

Cornerstone Pharmaceuticals, Inc. today announced the addition of Mary Crowley Cancer Research Centers to its roster of sites for its ongoing Phase I/II clinical trials of its first-in-class anti-cancer agent, CPI-613. Cornerstone is a leader in the discovery and development of cancer therapies that capitalize upon and disrupt the unique metabolic processes of cancer cells.

6 Aug 2010

Knapp Medical Center improves hospital's clinical performance with QualityConnect's QualityAdvisor program

Knapp Medical Center of Weslaco, Texas, saved $2.8 million in one year using the Premier healthcare alliance's QualityConnect™ performance improvement program.

6 Aug 2010

Death rates of patients who have heart bypass surgery drop: AHRQ

The proportion of patients who died in the hospital after having heart bypass surgery fell from 42 deaths per 1,000 admissions for the procedure to 24 per 1,000 - a rate of 43 percent between 2000 and 2006, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

6 Aug 2010

New laser technology for robotic prostate cancer surgery

One of the challenges of prostate cancer surgery is removing the cancer-affected gland without side effects. The procedure is estimated to cause long-term sexual dysfunction in half of men.Now, new published research by urologic surgeons at NewYork-Presbyterian Hospital/Columbia University Medical Center presents evidence that a new laser technology used with robotic prostate cancer surgery may reduce the risk of damaging the crucial nerves necessary for erections and urinary continence.

6 Aug 2010

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in first- and second-line treatment of Clostridium difficile infection, nearly 70 percent of surveyed infectious disease specialists and internists will use Optimer's fidaxomicin and nearly half will use Medarex/Merck's CDA1 and CDB1, one year after the launch of these agents. The lower recurrent/relapse rate associated with fidaxomicin and CDA1/CDB1 is the most influential attribute surveyed clinicians cite in their decisions to prescribe these emerging agents for CDI.

6 Aug 2010

Researchers recommends robotic prostatectomy over traditional open surgery method

While sharp debate continues among medical professionals as to whether a radical prostatectomy performed with the assistance of a robotic device is more beneficial than the traditional open surgery method, research just published by investigators at The Cancer Institute of New Jersey (CINJ) shows new evidence supporting the safety of the robotic procedure - including what is believed to be one of the lowest complication rates to date. CINJ is a Center of Excellence of UMDNJ-Robert Wood Johnson Medical School.

6 Aug 2010

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Alnylam Pharmaceuticals, Inc. a leading RNAi therapeutics company, announced today the publication of new research findings in the journal Nature describing the discovery and validation of the role of the gene Sort1 in the development of cardiovascular disease, including myocardial infarction (MI). This work was done with collaborators at University of Pennsylvania (UPenn) School of Medicine, Massachusetts General Hospital (MGH), and the Broad Institute. The collaborative effort combined genome-wide association studies (GWAS) and RNAi technology to identify and validate novel genes as targets for new therapies for heart disease.

6 Aug 2010

Study identifies options for restoring knee cartilage lubrication to prevent OA

An injury to the anterior cruciate ligament is fairly common, especially among young athletes. While it can often be corrected through surgery, the injury can lead to increased risk of developing degenerative joint diseases, including osteoarthritis. The problem is that fluid in the knee joint, which lubricates the cartilage, is impacted by the trauma of the injury and begins to deteriorate.

6 Aug 2010

VWR International signs agreement to acquire scientific distribution businesses of EBOS Group

VWR International, LLC, a leading global laboratory supply and distribution company, announced today that it has signed an agreement to acquire the scientific distribution businesses of EBOS Group Limited, subject to customary closing conditions. The parties anticipate completion of the transaction on or about September 1, 2010.

6 Aug 2010

Akonni Biosystems receives patent for TruTip Extraction Kits

Akonni Biosystems, a developer of low-cost, multiplex molecular diagnostic testing systems, today announced that the United States Patent and Trademark Office issued a patent on July 20, 2010 for its method for rapidly purifying nucleic acids. U.S. Patent No. 7,759,112 entitled, "Apparatus, system, and method for purifying nucleic acids" protects the Company's use of its pioneering nucleic acid binding matrix when inserted into a pipette tip, tubing or cartridge for nucleic acid purification. The patent is owned by Akonni Biosystems.

6 Aug 2010

Split-dosage method effective for bowel cleansing before colonoscopy: Study

A new study from researchers in Italy has found that a split-dosage schedule of bowel (colon) preparation is the most effective method for bowel cleansing before colonoscopy. Colonoscopies performed within six to eight hours of the end of preparation were associated with significantly better cleansing than those performed more than eight hours after the end of preparation. Two different types of bowel cleansing products were also assessed and researchers found that low-volume polyethylene glycol (PEG) plus ascorbic acid was as effective as high-volume PEG-electrolyte solution, but has superior palatability (or taste). This is the first study to demonstrate that the advantage of split-dosage intake is also true for low-volume bowel cleansing solutions.

6 Aug 2010

EMRs bring new risks as national push ramps up

Two electronic medical record snafus in two weeks at a Midwestern hospital chain are raising questions about the safety of such health IT systems, The Huffington Post Investigative Fund reports.

6 Aug 2010

NAEDI aims to correct survival gap in cancer diagnosis

Cancer Research UK today reveals that as many as 11,000 deaths from cancer could be prevented annually if Great Britain raised its survival figures to match those of the best performing countries in Europe.Cancer Research UK and national cancer director, Professor Mike Richards, believe that the most important reasons for the survival gap include poor awareness of the symptoms of cancer, late presentation to a GP and, late onward referral to hospital.

6 Aug 2010

New laboratory to speed up research for melanoma treatment set up at University of Bristol

A new Skin Cancer Research Fund Laboratory has been set up in Bristol to study cancer cells collected from skin cancer patients attending Frenchay Hospital. It is hoped the new facility will speed up research into treatments for malignant melanoma - the most deadly form of skin cancer. The new laboratory at the Microvascular Research Laboratories at the University of Bristol will be officially opened today (Tuesday August 22nd) by the director of the Skin Cancer Research Fund, Mr Paul Townsend.

6 Aug 2010

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Repligen Corporation today reported results for the first quarter of fiscal year 2011, ended June 30, 2010. Total revenue for the first quarter was $7,010,000 compared to total revenue of $5,061,000 for the first quarter of fiscal year 2010, an increase of $1,949,000 or 39%. Bioprocessing product revenue for the first quarter was $4,269,000 compared to $2,473,000 for the first quarter of fiscal 2010, an increase of $1,796,000 or 73%.

5 Aug 2010

Hospital News and Research

Salamander research findings bring scientists closer to future regenerative therapies

Nemours applauds Senate for passing bi-partisan Healthy, Hunger-Free Kids Act of 2010

Cornerstone Pharmaceuticals includes Mary Crowley Research Centers in CPI-613 clinical trials

Knapp Medical Center improves hospital's clinical performance with QualityConnect's QualityAdvisor program

Death rates of patients who have heart bypass surgery drop: AHRQ

New laser technology for robotic prostate cancer surgery

Fidaxomicin, CDA1/CDB1 effective for treating CDI : Report

Researchers recommends robotic prostatectomy over traditional open surgery method

Alnylam publishes research findings of Sort1 gene role in cardiovascular disease development

Study identifies options for restoring knee cartilage lubrication to prevent OA

VWR International signs agreement to acquire scientific distribution businesses of EBOS Group

Akonni Biosystems receives patent for TruTip Extraction Kits

Split-dosage method effective for bowel cleansing before colonoscopy: Study

EMRs bring new risks as national push ramps up

NAEDI aims to correct survival gap in cancer diagnosis

New laboratory to speed up research for melanoma treatment set up at University of Bristol

Repligen total revenue for first-quarter fiscal 2011 increases 39% to $7.01 million

Cornerstone Therapeutics second-quarter total net revenues increase 14% to $28.5 million

New article highlights importance of patient safety features in design of IV needleless connectors

New study on decision making for infants with complex life threatening illnesses

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News